SCHEMBL5233063

SCHEMBL5233063

CCOC(=O)c1c(-c2ccc(F)cc2)c2cc(Cl)ccc2c(=O)n1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.46
DPP4 P27487 3/20 0.45
MDM2 Q00987 2/20 0.45
MDM4 O15151 1/20 0.45
MAPK8 P45983 3/20 0.44
CENPE Q02224 2/20 0.43
ALOX15 P16050 2/20 0.43
CSF1R P07333 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
CYP1A2 P05177 1/20 0.43
XBP1 P17861 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233680 0.89 TACR1 (0.55) TACR1DPP4MAPK8CENPEALOX15
SCHEMBL5240987 0.88 GABRA2 (0.48) TACR1DPP4MAPK8CSF1RALDH1A1
SCHEMBL5230696 0.84 ALDH1A1 (0.55) TACR1DPP4MAPK8CSF1RALDH1A1
SCHEMBL5238214 0.84 TACR1 (0.51) TACR1DPP4MAPK8CENPE
SCHEMBL8989478 0.82 CENPE (0.53) TACR1CENPEALDH1A1HPGDKDM4E
SCHEMBL5231074 0.81 MAPK8 (0.46) TACR1DPP4MAPK8CSF1RALDH1A1
SCHEMBL7850580 0.80 MAPK14 (0.44) TACR1SMN1; SMN2
SCHEMBL5239340 0.80 ALDH1A1 (0.54) ALOX15ALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL6109300 0.79 MAPT (0.48) TACR1DPP4MAPK8ALDH1A1
SCHEMBL5236655 0.78 ALDH1A1 (0.46) ALOX15ALDH1A1HPGDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 TACR1 1624/4885DPP4 2/4885MDM2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.